‘Game-changer for autism’: 100-year-old drug reverses symptoms, study finds
A drug discovered more than 100 years ago may hold the key to combating autism symptoms, according to a study.Researcher Dr Robert Naviaux of the San Diego School of Medicine gave suramin, a drug first developed in 1916, to 10 autistic boys between the ages of five and 14, and noted transformative results.
“After the single dose, it was almost like a roadblock had been released,” he said. “If the future studies show that there’s continued health benefits, this could be a game-changer for families with autism.”
The study, which has been published in the Annals of Clinical and Translational Neurology, saw five of the participants receive suramin, while the remainder were given placebos. Included in the group were four non-verbal children – two six year olds and two 14 year olds.
“The six year old and the 14 year old who received suramin said the first sentences of their lives about one week after the single suramin infusion,” Naviaux told the UC San Diego Health website. “This did not happen in any of the children given the placebo.”
Research has shown that cells harden their membranes in response to attacks from viruses or pollutants. The reaction, known as ‘cellular danger response’ (CDR), is a common defense mechanism that allows cells to wait for danger to pass. Autism is thought to develop during early childhood when cells can become ‘stuck’ in this mode.
One parent, whose son had not spoken a full sentence in more than a decade, said: “Within an hour after the infusion, he started to make more eye contact with the doctor and nurses in the room. There was a new calmness at times, but also more emotion at other times.”
“He started to show an interest in playing hide-and-seek with his 16-year-old brother. He started practicing making new sounds around the house. He started seeking out his dad more.”
First tested on mice in 2013, this is the first time suramin has been administered to children.
For Naviaux, the challenge now is to widen his research to a bigger sample testing size. “This work is new and this type of clinical trial is expensive,” he said. “We did not have enough funding to do a larger study. And even with the funding we were able to raise, we had to go $500,000 in debt to complete the trial.” https://www.rt.com/usa/390222-autism-research-suramin-symptoms/
EXCLUSIVE: FDA Withholding Autopsy Results on People Who Died After Getting COVID-19 Vaccines
The FDA says it is barred from releasing medical files, but a drug safety advocate says that it could release the autopsies with personal information redacted.
The refusal was issued to The Epoch Times, which submitted a Freedom of Information Act for all autopsy reported obtained by the FDA concerning any deaths reported to the Vaccine Adverse Event Reporting System following COVID-19 vaccination.
Reports are lodged with the system when a person experiences an adverse event, or a health issue, after receiving a vaccine. The FDA and other agencies are tasked with investigating the reports. Authorities request and review medical records to vet the reports, including autopsies.
The FDA declined to release any reports, even redacted copies.
The FDA cited federal law, which enables agencies to withhold information if the agency “reasonably foresees that disclosure would harm an interest protected by an exemption,” with the exemption being “personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.”
Federal regulations also bar the release of “personnel, medical and similar files the disclosure of which constitutes a clearly unwarranted invasion of personal privacy.”
The Epoch Times has appealed the denial, in addition to the recent denial of results of data analysis of VAERS reports.
‘Easily Be Redacted’
Kim Witczak, a drug safety advocate who advises the FDA as part of the Psychopharmacologic Drugs Advisory Committee, said that the reports could be released with personal information blacked out.
“The personal information could easily be redacted without losing the potential learnings from [the] autopsy,” Witczak told The Epoch Times via email.
People make the choice to submit autopsy results to the Vaccine Adverse Event Reporting System, Witczak noted.
“If someone submits their experience to VAERS they want and expect to have it investigated by the FDA. This includes autopsy reports,” she said.
Autopsies are examinations of deceased persons performed to determine the cause of death.
“Autopsies can be an important part of postmortem analysis and should be done especially with increased deaths following COVID-19 vaccination,” Witczak said.
FDA Responds
An FDA spokesperson noted that deaths following COVID-19 vaccination are rare, citing the number of reports made to VAERS.
As of Sept. 14, 16,516 reports of death following COVID-19 vaccination have been reported. Approximately 616 million doses have been administered in the United States through September.
The spokesperson declined to say whether the FDA would ever release the autopsy results, but pointed to a paper authored by researchers with the FDA and the Centers for Disease Control and Prevention (CDC).
The paper, which has not been peer reviewed, analyzed the approximately 9,800 reports of death to VAERS following COVID-19 vaccination lodged from Dec. 14, 2020, to Nov. 17, 2021. Researchers found that reporting rates were lower than the expected all-cause mortality rates.
“Trends in reporting rates reflected known trends in background mortality rates. These findings do not suggest an association between vaccination and overall increased mortality,” the researchers wrote.
The researchers noted that prior studies have found that adverse events reported to VAERS are an undercount of the true number of events.
In 2021, we had the most reports EVER of suspected CSAM (“CP”) to The National Center For Missing & Exploited Children. That number was 29.3 MILLION! Yet, media propagandists like Mike Rothschild spend a lot of time trying to convince you that it isn’t a problem. Why?
